Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 6
---
 of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and in
an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
a general meeting of shareholders, or November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.001
nominal value each into one ordinary share of £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each,
each the November Subdivision, which became effective on November 25, 2024 and (y) adopt new articles of association, or the Articles
of Association, which make consequential amendments to the existing articles of association of the Company to reflect the November Subdivision.
As is standard for deferred shares, each B Deferred Share and C Deferred Share has very limited rights and is effectively valueless. The
B Deferred Shares and C Deferred Shares have the rights and restrictions as set out in the Articles of Association and do not entitle
the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution.

| 2 |

The change in the number of
Ordinary Shares resulting from the reverse stock split and change in the number of Depositary Shares (and the underlying Ordinary Shares)
resulting from the change in ratio, including any changes resulting from fractional Depositary Shares not being issued to holders in connection
with the Depositary Share ratio change, has been applied retroactively to all share and per share amounts presented in this prospectus,
to the extent applicable. As a result of retroactively applying changes resulting from fractional Depositary Shares not being issued to
holders in connection with the Depositary Share ratio change, the amount of Ordinary Shares issued in prior transactions may not equal
the amount of Depositary Shares such Depositary Shares are currently exercisable for.

<div align='center'>MARKET AND INDUSTRY DATA</div>

Market data and certain industry
data and forecasts used throughout this prospectus were obtained from sources we